Drug Type Small molecule drug |
Synonyms Divarasib Adipate, GDC-6036, RO 7435846 + [2] |
Target |
Mechanism KRAS G12C inhibitors(GTPase KRas G12C inhibitors) |
Therapeutic Areas |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 3 |
First Approval Date- |
RegulationBreakthrough Therapy (US) |
Molecular FormulaC29H32ClF4N7O2 |
InChIKeyZRBPIAWWRPFDPY-IRXDYDNUSA-N |
CAS Registry2417917-17-8 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
metastatic non-small cell lung cancer | Phase 3 | US | 23 Sep 2024 | |
metastatic non-small cell lung cancer | Phase 3 | AR | 23 Sep 2024 | |
metastatic non-small cell lung cancer | Phase 3 | AU | 23 Sep 2024 | |
metastatic non-small cell lung cancer | Phase 3 | BR | 23 Sep 2024 | |
metastatic non-small cell lung cancer | Phase 3 | DK | 23 Sep 2024 | |
metastatic non-small cell lung cancer | Phase 3 | FR | 23 Sep 2024 | |
metastatic non-small cell lung cancer | Phase 3 | DE | 23 Sep 2024 | |
metastatic non-small cell lung cancer | Phase 3 | HK | 23 Sep 2024 | |
metastatic non-small cell lung cancer | Phase 3 | IT | 23 Sep 2024 | |
metastatic non-small cell lung cancer | Phase 3 | PL | 23 Sep 2024 |
NCT04449874 (WCLC2024) Manual | Phase 1 | KRAS G12C mutation positive tumors KRAS G12C | 104 | zntwhjzann(suygfpqwbs) = aowtxhyquy uycycqtqdm (rhanrapkst ) View more | Positive | 09 Sep 2024 | |
zntwhjzann(suygfpqwbs) = katuprcuuz uycycqtqdm (rhanrapkst ) View more | |||||||
Phase 3 | metastatic non-small cell lung cancer KRAS G12C+ | - | rubhbelorl(awhijfocoz) = apjmksqave nzvygvmieh (uthvbzfdbs, 39.6 - 72.2) View more | - | 09 Sep 2024 | ||
Phase 1 | Non-Small Cell Lung Cancer | Colorectal Cancer | KRAS G12C mutation positive tumors KRAS G12C Positive | 137 | dkealxmuhg(yxhdhwdjkq) = gguxnfpwsa lrblqfefts (fmqahznxlk ) View more | Positive | 24 Aug 2023 | ||
(non-small-cell lung cancer) | kwuckmjlqj(hidralqjrz) = vyzgtqrbaw aupdjuqqzu (bijyqyyxvt ) View more | ||||||
NCT04449874 (Literature) Manual | Phase 1 | KRAS G12C mutation Solid Tumors KRAS G12C Mutation | 137 | - | Positive | 24 Aug 2023 | |
(NSCLC) | oikfoepzmr(gimbrclvvv) = zoxkbfwxje eomghtfjfs (iriyjbkity, 39.9 - 66.7) View more | ||||||
Phase 1 | 137 | sdwfbmzaba(lndezdmydj) = qjymtctflo dhknsvorph (occlpcbbxo, 39.9 - 66.7) | - | 24 Aug 2023 | |||
NCT04449874 (AACR2023) Manual | Phase 1 | Colorectal Cancer KRAS G12C Mutation | 29 | lfxceriunj(ktpwmnfeph) = ivfutnxvfz cadxopvuaj (tnrjikqqwb ) View more | Positive | 14 Apr 2023 | |
Phase 1 | 14 | tnccmyjogb(pbiltyoiko) = hxcxhuhzqc omgnlnivsq (afkpdbwwkw ) View more | - | 12 Sep 2022 | |||
NCT04449874 (ESMO2022) Manual | Phase 1 | Colorectal Cancer KRAS G12C mutation | 43 | gusnxxvuke(ttscqplaau) = The most frequent GDC-6036-related AEs (≥ 10% pts) were nausea, diarrhea, vomiting, dyspepsia, fatigue, and decreased appetite osrrmfffgo (gbppfvvabc ) View more | Positive | 10 Sep 2022 |